Whenever a new development is announced in cancer diagnosis, treatment and management it comes with a lot of curiosity as for its effectiveness. Scholars and researcher have for a long time studied oncology which has improved cancer management. IntegraGen is the new intrusion into the Oncotarget journals which analytically look at the relationship between Mir-31-3P expression and Cetuximab Efficiency of cancer patients under the anti-EGFR therapy.Patients have been enrolled in the NEW EPOC clinical trial in an attempt to link genomic information or profile and diagnostic tools used in oncology. The University College London Cancer Institute conducted the study lead by Prof. John Bridgewater who is also an oncologist. A conclusive clinical report from the survey is that patients with metastatic colorectal cancer are better of managed through anti-EGFR therapies.
Director of Molecular Diagnostics at IntegraGen, Yann Gaston Mathe in analyzing a peer-reviewed publication on oncology established that reliable diagnosis can accurately be achieved through measuring miR-31-3p in tumors from patients with metastatic colorectal cancer. The miR-31-3P expression testing has brought cancer approaches to precision. IntegraGen in building trust is at the baby stages of establishing a miRpredX 31-3p kit as a development of CERBA laboratories.Mirpredx 31-3p Tests help predict a patient’s profile including anti-EGFR and VEGF therapy. They are the markers of survival rate in metastatic colorectal cancer patients and response to chemotherapy. FOLFIRI plus bevacizumab treatment was also proven to work better than chemotherapy. Something worth noting is the prevalence of colorectal cancer is more common in men than women with 1.3 million cases reported annually. 345,000 and 135,000 new cases are from Europe and the United States respectively.
This an open-access medical journals in medicine and more specifically in oncology. Impact journals publish these publications on a weekly basis. This platform was established in 2010 with the chief editor being Andrei V. Gudkov. Oncotarget is in collaboration with the Roswell Park Cancer Institute. IntegraGen will be the new inclusion into Oncotarget’s oncology medical journals. Journals are in the English language in the Science Citation Index and according to Scopus. Oncotarget has 3.0 licensing of Creative Commons Attribution and an impact factor of 5.008.